vimarsana.com

Page 81 - ஒன்றுபட்டது மாநிலங்களில் ஆஸ்திரேலியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

史上首次!日本聯合印度在東海搞小動作

史上首次!日本聯合印度在東海搞小動作
hkcna.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hkcna.hk Daily Mail and Mail on Sunday newspapers.

พารู้จักแพลตฟอร์ม Borderless lgbt สำหรับกลุ่มสุขภาพ LGBT

พารู้จักแพลตฟอร์ม Borderless lgbt สำหรับกลุ่มสุขภาพ LGBT
springnews.co.th - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from springnews.co.th Daily Mail and Mail on Sunday newspapers.

New critical minerals portal shows Australia ready for investment

Date Time New critical minerals portal shows Australia ready for investment Australia’s position as a global critical mineral supplier will be further enhanced through a new dataset developed in partnership with the United States and Canada. The Critical Minerals Mapping Initiative online portal, released today, contains the world’s largest dataset of critical minerals in and around ore deposits – more than 7000 mineral samples from over 60 countries. It shows the occurrence of critical minerals such as cobalt, lithium and rare Earth elements predominantly across Australia, the United States and Canada, and can help identify new critical mineral provinces. Minister for Resources, Water and Northern Australia Keith Pitt said this dataset could open new global supply chain opportunities for Australia.

百奥赛图/祐和医药YH001和YH003二期临床试验双双获得FDA批准-美通社PR-Newswire

北京2021年6月29日 /美通社/ 百奥赛图公司旗下全资子公司祐和医药作为一家致力于开发具有自主知识产权抗体类药物的生物医药公司,今日宣布美国食品药品管理局(FDA)批准其在研创新药抗CTLA-4单抗YH001和抗CD40单抗YH003人源化单克隆抗体注射液的2个二期临床试验IND申请。 FDA同意祐和医药在美国开展2项二期临床试验:(1)一项评价YH001联合君实生物特瑞普利注射液(抗PD-1单抗)治疗晚期非小细胞肺癌和肝癌的开放,非随机化,多中心II期临床研究;(2)一项评价YH003联合特瑞普利注射液治疗PD-1耐受的不可切除/转移性黑色素瘤和胰腺导管腺癌(PDAC)患者的安全性和有效性的II期、多中心、开放标签研究。这2项二期临床试验均为国际多中心临床研究,参加国家将包括美国,澳大利亚及中国等。 YH001是一款以CTLA-4为靶点的人源化IgG1单克隆抗体,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.